Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943965 | 0.85 | CA1 (0.53) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL2152406 | 0.83 | CA1 (0.53) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL29651074 | 0.82 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL70712 | 0.82 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL29651058 | 0.82 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL69747 | 0.80 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL30574349 | 0.80 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL29508473 | 0.80 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL3598042 | 0.80 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL28205764 | 0.80 | MAPK1 (0.43) | MAPK1KDM4EL3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4713306-A1 | NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3768269-B1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-20 | — | — | EP | disclosed |
| EP-4077306-B1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| WO-1996022292-A1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5521173-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| US-5512581-A | ANTIINFLAMMATORY AGENT | ABBOTT LABORATORIES (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1996002507-A1 | IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0302389-B1 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-22 | — | — | EP | disclosed |
| US-5214152-A | Insecticides, miticides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0529680-A2 | Intermediates, their production and their use for preparing alpha-unsaturated amines | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5175301-A | Insecticide, miticide, pesticide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| EP-0509559-A2 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0302389-A2 | Alpha-unsaturated amines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | MAPK1 1739/4885KDM4E 58/4885L3MBTL1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.